(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Supreme Court's Decision Sparks Biden's Call for Inclusive Education

June 30th, 2023

President Biden has announced a series of actions aimed at promoting educational opportunity and diversity in colleges and universities. The recent Supreme Court's decision in two cases — Students for Fair Admissions Inc. (SFFA) v. President an. Read more

Breaking: Renalytix's KidneyIntelX.dkd FDA-Approved, VSE Secures Up to $565M Contract

June 29th, 2023

Shares of Renalytix plc (Nasdaq: RNLX) surged over 25% in after-hours trading following the company's announcement of receiving De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.. Read more

Surging and Slumping: Aurinia Pharmaceuticals and Root Make Headlines

June 29th, 2023

Shares of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) witnessed a significant surge of over 10% in after-hours trading, driven by the company's announcement of initiating an exploration of strategic alternatives. The Board of Aurinia will carefull. Read more

Earnings Buzz and Reactions: Accolade, Progress Software, and Nike

June 29th, 2023

Accolade, Inc. (Nasdaq: ACCD) released its first-quarter fiscal 2024 earnings report, revealing a loss of $0.52 per share, which was better than the consensus estimate of a loss of $0.62 per share. The company also reported quarterly sales of $93.20 . Read more

SEC Charges Former Pfizer Statistician with Insider Trading Ahead of COVID-19 Announcement

June 29th, 2023

Employee and friend traded ahead of Pfizer’s “game-changer” announcement on the success of its Paxlovid trial FOR IMMEDIATE RELEASE 2022-123 Washington D.C. / CRWE PRESS RELEASE / June 29, 2023 -  The Securities and Exch. Read more

BREAKING: BioXcel's Regulatory Inquiry Status Sends Shares Tumbling

June 29th, 2023

Shares of BioXcel Therapeutics, Inc.? (Nasdaq: BTAI) plunged by over 50% in premarket trading following the company's disclosure of a regulatory inquiry into the development of BXCL501, as revealed in a regulatory filing with the SEC. Despite this. Read more

Joby's Pre-Market Surge, Nano Dimension's Milestone Quarter: What You Need to Know

June 29th, 2023

Shares of Joby Aviation, Inc. (NYSE: JOBY) experienced a significant surge of over 10% in pre-market trading following the announcement of an equity investment by SK Telecom Co., Ltd.? (NYSE: SKM), a prominent telecommunications company in South Kore. Read more

Earnings Beat: BlackBerry, Greenbrier, and Acuity Brands in the Spotlight

June 29th, 2023

Shares of BlackBerry Limited (NYSE: BB) experienced a significant surge of over 10% in pre-market trading following the release of better-than-expected financial results. The company delivered a surprise profit for the first quarter of fiscal 2024. Read more

Bullishness: ZI, GPC, SQSP, DE, VVI, WIX, ARRY, GDDY - Top Buy Ratings

June 29th, 2023

ZoomInfo Technologies Inc. (Nasdaq: ZI), a leading provider of go-to-market intelligence solutions, received coverage initiation from Needham with a Buy rating and a price target of $35.  Despite closing at $25.61 on Wednesday, the stated pri. Read more

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

June 28th, 2023

Silver Spring, MD / CRWE PRESS RELEASE / June 28, 2023 -  Today, the U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treat. Read more